Communiqués Mineralys Therapeutics, Inc.

Actions

MLYS

US6031701013

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
14,58 ^USD	0,00 %		+13,11 %	+69,53 %

20/06	Un initié de Mineralys Therapeutics a vendu des actions pour une valeur de 592 022 $, selon un récent dépôt auprès de la SEC	MT
14/06	Mineralys Therapeutics, Inc. annonce des changements au sein de son conseil d'administration	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors	14/06	AQ
Mineralys Therapeutics : Corporate Overview June 2024	10/06	PU
Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	03/06	AQ
Mineralys Therapeutics : Corporate Overview May 2024	13/05	PU
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05	AQ
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference	06/05	AQ
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024	02/05	AQ
Mineralys Therapeutics : Corporate Overview March 2024	21/03	PU
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	21/03	AQ
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024	13/03	AQ
Mineralys Therapeutics Announces $120 Million Private Placement Financing	08/02	AQ
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference	29/01	AQ
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer	04/01	AQ
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension	21/12	AQ
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023	11/11	AQ
Mineralys Therapeutics to Participate in Three Upcoming Conferences	09/11	AQ
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	07/11	AQ
Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting	02/11	AQ
Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023	31/10/23	AQ
Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023	13/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Mineralys Therapeutics, Inc.

Actions

MLYS

US6031701013

Communiqués

Filtres